{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:28:48Z","timestamp":1782250128249,"version":"3.54.5"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The discovery of novel biomarkers that predict treatment response in advanced cancer patients requires acquisition of high-quality tumor samples. As cancer evolves over time, tissue is ideally obtained before the start of each treatment. Preferably, samples are freshly frozen to allow analysis by next-generation DNA\/RNA sequencing (NGS) but also for making other emerging systematic techniques such as proteomics and metabolomics possible. Here, we describe the first 469 image-guided biopsies collected in a large collaboration in The Netherlands (Center for Personalized Cancer Treatment) and show the utility of these specimens for NGS analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Image-guided tumor biopsies were performed in advanced cancer patients. Samples were fresh frozen, vital tumor cellularity was estimated, and DNA was isolated after macrodissection of tumor-rich areas. Safety of the image-guided biopsy procedures was assessed by reporting of serious adverse events within 14 days after the biopsy procedure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Biopsy procedures were generally well tolerated. Major complications occurred in 2.1%, most frequently consisting of pain. In 7.3% of the percutaneous lung biopsies, pneumothorax requiring drainage occurred. The majority of samples (81%) contained a vital tumor percentage of at least 30%, from which at least 500\u2009ng DNA could be isolated in 91%. Given our preset criteria, 74% of samples were of sufficient quality for biomarker discovery. The NGS results in this cohort were in line with those in other groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Image-guided biopsy procedures for biomarker discovery to enable personalized cancer treatment are safe and feasible and yield a highly valuable biobank.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0085","type":"journal-article","created":{"date-parts":[[2016,9,24]],"date-time":"2016-09-24T03:19:21Z","timestamp":1474687161000},"page":"33-40","source":"Crossref","is-referenced-by-count":29,"title":["Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies"],"prefix":"10.1093","volume":"22","author":[{"given":"Sander","family":"Bins","sequence":"first","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Departments of Medical Oncology, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert A.","family":"Cirkel","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Department of Medical Oncology University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa G.","family":"Gadellaa-Van Hooijdonk","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Department of Medical Oncology University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Weeber","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Departments of Molecular Oncology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac J.","family":"Numan","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Center for Molecular Medicine, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette H.","family":"Bruggink","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Central Biobank, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Departments of Pathology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Willems","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Departments of Pathology, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter B.","family":"Veldhuis","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Radiology University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Thoracic Oncology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J.","family":"de Knegt","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Gastroenterology and Hepatology Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco J.","family":"Koudijs","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Department of Medical Oncology University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"van Werkhoven","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Biometrics, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Departments of Medical Oncology, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Cuppen","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Center for Molecular Medicine, Utrecht, The Netherlands"},{"name":"Cancer Genomics Centre, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Departments of Medical Oncology, Rotterdam, The Netherlands"},{"name":"Cancer Genomics Centre, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Medical Oncology and Clinical Pharmacology Antoni van Leeuwenhoek\u2014The Netherlands Cancer Institute, Amsterdam, The Netherlands"},{"name":"Department of Pharmaceutical Sciences, Science Faculty Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile E.","family":"Voest","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Department of Pharmaceutical Sciences, Science Faculty Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies H.G.","family":"Langenberg","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Department of Medical Oncology University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja J.A.","family":"de Jonge","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Departments of Medical Oncology, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Medical Oncology and Clinical Pharmacology Antoni van Leeuwenhoek\u2014The Netherlands Cancer Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn P.","family":"Lolkema","sequence":"additional","affiliation":[{"name":"Center for Personalized Cancer Treatment, Utrecht, The Netherlands"},{"name":"Departments of Medical Oncology, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"key":"2021122506430318200_onco12063-bib-0001","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122506430318200_onco12063-bib-0002","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1101\/gr.161026.113","article-title":"Genomic and transcriptomic plasticity in treatmentnaive ovarian cancer","volume":"24","author":"Hoogstraat","year":"2014","journal-title":"Genome Res"},{"key":"2021122506430318200_onco12063-bib-0003","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nm.3915","article-title":"Toward understanding and exploiting tumor heterogeneity","volume":"21","author":"Alizadeh","year":"2015","journal-title":"Nat Med"},{"key":"2021122506430318200_onco12063-bib-0004","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122506430318200_onco12063-bib-0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"2021122506430318200_onco12063-bib-0006","doi-asserted-by":"crossref","first-page":"e102452","DOI":"10.1371\/journal.pone.0102452","article-title":"Quantifying metabolic heterogeneity in head and necktumorsin realtime: 2-DG uptake is highest in hypoxic tumor regions","volume":"9","author":"Nakajima","year":"2014","journal-title":"PLoS One"},{"key":"2021122506430318200_onco12063-bib-0007","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2967\/jnumed.114.144055","article-title":"18F-FDG PET uptake characterization through texture analysis: Investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort","volume":"56","author":"Hatt","year":"2015","journal-title":"J Nucl Med"},{"key":"2021122506430318200_onco12063-bib-0008","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2967\/jnumed.107.046870","article-title":"Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGDautora- diography","volume":"49","author":"Picchio","year":"2008","journal-title":"J Nucl Med"},{"key":"2021122506430318200_onco12063-bib-0009","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122506430318200_onco12063-bib-0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/pcmr.12347","article-title":"Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib","volume":"28","author":"Hoogstraat","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"2021122506430318200_onco12063-bib-0011","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1158\/1078-0432.CCR-13-0661","article-title":"Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E- mutated cutaneous melanoma successfully rechallenged after progression","volume":"19","author":"Romano","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2021122506430318200_onco12063-bib-0012","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.15252\/emmm.201404914","article-title":"Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts","volume":"7","author":"Kemper","year":"2015","journal-title":"EMBO Mol Med"},{"key":"2021122506430318200_onco12063-bib-0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122506430318200_onco12063-bib-0014","volume-title":"Common Terminology Criteria for Adverse Events (v4.0) [NIH Publication 09-7473]","author":"National Cancer Institute","year":"2009"},{"key":"2021122506430318200_onco12063-bib-0015","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/nprot.2011.396","article-title":"Multiplexed array-based and in-solution genomic enrichment for flexible and cost-effective targeted next-generation sequencing","volume":"6","author":"Harakalova","year":"2011","journal-title":"Nat Protoc"},{"key":"2021122506430318200_onco12063-bib-0016","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/1078-0432.CCR-11-1965","article-title":"Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment","volume":"18","author":"Vermaat","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122506430318200_onco12063-bib-0017","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2021122506430318200_onco12063-bib-0018","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: A Map Reduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"2021122506430318200_onco12063-bib-0019","first-page":"11.10.1","article-title":"From fastq data to high confidence variant calls: The genome analysis toolkit best practices pipeline","volume":"43","author":"Auwera","year":"2013","journal-title":"Curr Protoc Bioinformatics"},{"key":"2021122506430318200_onco12063-bib-0020","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4161\/fly.19695","article-title":"A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3","volume":"6","author":"Cingolani","year":"2012","journal-title":"Fly (Austin)"},{"key":"2021122506430318200_onco12063-bib-0021","doi-asserted-by":"crossref","first-page":"E2393","DOI":"10.1002\/humu.22376","article-title":"dbNSFP v2.0: A database of human non-synonymous SNVs and their functional predictions and annotations","volume":"34","author":"Liu","year":"2013","journal-title":"Hum Mutat"},{"key":"2021122506430318200_onco12063-bib-0022","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: Accurate somatic small-variant calling from sequenced tumor-normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"2021122506430318200_onco12063-bib-0023","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"2021122506430318200_onco12063-bib-0024","volume-title":"Haplotype-based variant detection from short-read sequencing","author":"Garrison"},{"key":"2021122506430318200_onco12063-bib-0025","first-page":"2971","article-title":"Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation","volume":"7","author":"Dowlati","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122506430318200_onco12063-bib-0026","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/annonc\/mdr383","article-title":"Sequential research-related biopsies in phase I trials: Acceptance, feasibility and safety","volume":"23","author":"Gomez-Roca","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122506430318200_onco12063-bib-0027","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/cncr.27916","article-title":"Feasibility and safety of sequential research-related tumor core biopsies in clinical trials","volume":"119","author":"Lee","year":"2013","journal-title":"Cancer"},{"key":"2021122506430318200_onco12063-bib-0028","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/ijc.27817","article-title":"Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial","volume":"132","author":"Tran","year":"2013","journal-title":"Int J Cancer"},{"key":"2021122506430318200_onco12063-bib-0029","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7863\/jum.2003.22.2.193","article-title":"Complications after interventional sonography of focal liver lesions: A 22-year single-center experience","volume":"22","author":"Giorgio","year":"2003","journal-title":"J Ultrasound Med"},{"key":"2021122506430318200_onco12063-bib-0030","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2214\/AJR.08.2122","article-title":"Incidence of bleeding after 15,181 percutaneous biopsies and the role of aspirin","volume":"194","author":"Atwell","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"2021122506430318200_onco12063-bib-0031","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/0016-5085(90)91167-5","article-title":"A 21-year experience with major hemorrhage after percutaneous liver biopsy","volume":"99","author":"McGill","year":"1990","journal-title":"Gastroenterology"},{"key":"2021122506430318200_onco12063-bib-0032","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1634\/theoncologist.2011-0043","article-title":"Outcomes of research biopsies in phase I clinical trials: the MD Anderson cancer center experience","volume":"16","author":"El-Osta","year":"2011","journal-title":"The Oncologist"},{"key":"2021122506430318200_onco12063-bib-0033","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"2021122506430318200_onco12063-bib-0034","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrg2302","article-title":"Research ethics and the challenge of whole-genome sequencing","volume":"9","author":"McGuire","year":"2008","journal-title":"Nat Rev Genet"},{"key":"2021122506430318200_onco12063-bib-0035","doi-asserted-by":"crossref","DOI":"10.1038\/ejhg.2016.27","article-title":"Unsolicited findings of next- generation sequencing for tumor analysis within a Dutch consortium: Clinical daily practice reconsidered","author":"Bijlsma","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"2021122506430318200_onco12063-bib-0036","doi-asserted-by":"crossref","first-page":"e17163","DOI":"10.1371\/journal.pone.0017163","article-title":"Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue","volume":"6","author":"Mittempergher","year":"2011","journal-title":"PLoS One"},{"key":"2021122506430318200_onco12063-bib-0037","doi-asserted-by":"crossref","first-page":"e98187","DOI":"10.1371\/journal.pone.0098187","article-title":"Next- generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue","volume":"9","author":"Hedegaard","year":"2014","journal-title":"PLoS One"},{"key":"2021122506430318200_onco12063-bib-0038","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1634\/theoncologist.2015-0112","article-title":"Variation in the attitudes of medical oncologists toward research biopsies in patients with metastatic breast cancer","volume":"20","author":"Seah","year":"2015","journal-title":"The Oncologist"},{"key":"2021122506430318200_onco12063-bib-0039","doi-asserted-by":"crossref","first-page":"6478","DOI":"10.1158\/1078-0432.CCR-12-1384","article-title":"Publication and reporting conduct for pharmacodynamic analyses of tumor tissue in early-phase oncology trials","volume":"18","author":"Freeman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122506430318200_onco12063-bib-0040","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2015.63.6126","article-title":"Analysis of impact of post-treatment biopsies in phase I clinical trials","volume":"34","author":"Sweis","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122506430318200_onco12063-bib-0041","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ctrv.2015.02.009","article-title":"The landscape of precision cancer medicine clinical trials in the United States","volume":"41","author":"Roper","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"2021122506430318200_onco12063-bib-0042","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature12831","article-title":"Inconsistency in large pharmacogenomic studies","volume":"504","author":"Haibe-Kains","year":"2013","journal-title":"Nature"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0085","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/1\/33\/41913236\/oncolo_22_1_33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/1\/33\/41913236\/oncolo_22_1_33.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:44:42Z","timestamp":1640414682000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/1\/33\/6438549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,17]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0085","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1,1]]},"published":{"date-parts":[[2017,1,1]]}}}